



Basic, Translational, Preclinical **Biomedical Research** *in Cancer and AIDS*

Frederick National Laboratory

The Frederick National Laboratory for Cancer Research (FNLCR) is a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. FNLCR is one of about 40 U.S. national laboratories and the only national laboratory devoted exclusively to biomedical research.

FNLCR, like other national laboratories, combines private business practices with government infrastructure for quick action, flexibility, and innovation. FNLCR, as a government-owned, contractor-operated facility, serves as a strategic technology and applied research center for its sponsor, the National Cancer Institute. The prime contractor for Frederick National Laboratory is Leidos Biomedical Research, Inc.

Academic and government researchers locally and across the nation rely on Frederick National Laboratory for:


- Biomarker identification and validation
- Translational genomics
- Next-generation preclinical assay development
- Oncology-focused computational science
- Production of first-in-human, clinical-grade biopharmaceuticals

- Acceleration of nanotechnology applications for treatments and diagnostics
- Preclinical model development, validation, and testing

FNLCR can quickly adapt its programs to maintain a strategic focus and keep pace with new discoveries, development opportunities, and biomedical priorities.

Broad and Highly Developed Core Competencies

Since its inception as the Frederick Cancer Research and Development Center in 1972, FNLCR has become a valuable national resource for cancer- and AIDS-related R&D. Our core competencies rely on scientific depth, cutting-edge technologies, and enabling infrastructure in the areas of information sciences and high-performance computing; molecular analysis across the “omics” spectrum; preclinical models development; nanomedicine; multi-modality imaging; HIV/AIDS research; and biopharmaceutical manufacturing for human clinical trials. Congruent with the 2009 White House Strategy for American Innovation, FNLCR and its partners cooperate to overcome translational research barriers and succeed in advancing therapeutics and diagnostics development for patients.



Colocation Opportunities

In addition to our campus at Fort Detrick in Frederick, Maryland, FNLCR operates the Advanced Technology Research Facility (ATRF) at the nearby Riverside Research Park. This state-of-the-art, 330,000-square-foot center concentrates research and development laboratories involved in genetics and genomics, proteomics and protein chemistry, metabolomics, nanotechnology, advanced biomedical imaging, bioinformatics, and scientific computing. In addition, cGMP manufacturing and process development are performed at the ATRF's plant for specialty biologicals.

Partnership space within the ATRF is designed for synergistic colocation, allowing for side-by-side collaborations with other government agencies, life science companies, academic institutions, and nonprofit research organizations. The overall goal is to accelerate strategic applications of advanced technologies for the translation of research discoveries into solutions for people with cancer and AIDS.

Flexibility in Partnering

FNLCR has a wide range of business mechanisms to accommodate different types of partnerships, including contractor-administered Cooperative Research and Development Agreements (cCRADAs). FNLCR uses the cCRADA to streamline development of R&D collaborations, respond more rapidly to opportunities, and manage intellectual property for technology transfer. This partnership mechanism also enables FNLCR contractor Leidos Biomed to receive funds directly from partners to offset the costs associated with collaborations. Using the cCRADA mechanism, academic, nonprofit, and commercial researchers have greater access to FNLCR's science, technology, and expertise.

The combination of advanced technologies, a sharp focus on partnerships, and a new, world-class facility provides a highly capable and cohesive translational research engine. FNLCR is moving to accelerate progress in cancer and AIDS research, stimulate research collaboration, and create partnerships. These activities represent what it will take to realize a new vision for maximizing the impact of scientific discovery on human health.

For more information, please contact:

Dr. Andrew Quong
 Director, Partnership Development Office
 Leidos Biomedical Research, Inc.
 Frederick National Laboratory for Cancer Research
andrew.quong@nih.gov

Dr. Nguyen K. Nguyen
 Partnership Alliances Manager
 Leidos Biomedical Research, Inc.
 Frederick National Laboratory for Cancer Research
nguyen.nguyen2@nih.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES
 National Institutes of Health
 National Cancer Institute

The Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute

<http://frederick.cancer.gov/partnerships>

